Eli Lilly and Company (LLY)
Track the next or latest earnings date for Eli Lilly and Company, review consensus estimates, and see cached AI analysis for recent quarterly results.
Recent earnings news
finance.yahoo.com · 1 day ago
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Eli Lilly (LLY) Stock May Trade At A Cash Flow Discount But An Earnings Premiumfinance.yahoo.com · 2 days ago
Eli Lilly stock has surged over the past five years, and at around US$1,213 a share, investors are weighing a sharp share price gain against signals that the stock screens as expensive on several checks even as a Discounted Cash Flow (DCF) estimate points to upside.
Eli Lilly (LLY) Stock Surges Past $1,200 on Blockbuster Earnings and Oral GLP-1 Launch - Blockonomiblockonomi.com · 2 days ago
Eli Lilly (LLY) stock analysis: Q1 2026 earnings beat, Foundayo oral GLP-1 launch, $20B+ acquisitions, and what analysts expect next for shares.
Eli Lilly Stock (LLY) Opinions on Medicare Coverage and Drug Pipeline Advancements | Quiver Quantitativewww.quiverquant.com · 2 days ago
Traders reference earnings multiples relative to projected growth from new indications and AI-driven drug development initiatives. Sentiment remains focused on long-term fundamentals amid short-term market fluctuations. Note: This discussion summary was generated from an AI condensation of post data…
What Eli Lilly Stock Said When It Had Too Much Business | Trefiswww.trefis.com · 19 hours ago
Before the share price caught on, the drugmaker was dealing with a problem most companies only dream of, and it was the clearest sign a surge was building. It’s one of the market’s great ironies: the best sign a stock is about to run isn’t always a story about finding growth.
Latest earnings date
Time not specified
Fiscal quarter: 2025-12-31
EPS estimate: $7.49
Revenue estimate: N/A
Market cap: $1014.67B
AI earnings summary
Lilly issued strong 2026 guidance with revenue expected between $80-83 billion (vs analyst estimates of $77.62 billion) and non-GAAP EPS of $33.50-35.00 (vs estimates of $33.23). The midpoint represents 25% revenue growth despite expected global pricing declines from Trump administration deals.
Sentiment and reaction
Sentiment score: +90.00%
Post-earnings price reaction: +7.00%
EPS
Estimate: $7.49
Actual: $7.39
Surprise: -1.34%
Revenue
Estimate: $17.96B
Actual: $19.29B
Surprise: +7.42%
Financial highlights
• Revenue increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound • Net income of $6.6 billion, up 50% year-over-year • Gross margin increased 43% to $15.9 billion (82.5% margin, up 0.3 percentage points) • Mounjaro revenue surged 110% to $7.4 billion in Q4 • Zepbound revenue jumped 122% to $4.2 billion in Q4 • U.S. revenue climbed to $12.9 billion driven by 50% volume increase • International revenue grew 43% to $6.4 billion with 38% volume growth • R&D expenses increased 26% to $3.8 billion (20% of revenue) • Marketing/administrative expenses up 29% to $3.1 billion • Effective tax rate was 19.7% vs 12.5% prior year • Non-GAAP EPS of $7.54 vs $5.32 prior year (42% increase)
Recent earnings history
Browse the calendar week| Date | Quarter | Report window | EPS est. | Revenue est. |
|---|---|---|---|---|
| Feb 05, 2026 | 2025-12-31 | Time not specified | $7.49 | N/A |